Suspicions Persist Over Vytorin's Cancer Risk

Law360, New York (September 2, 2008, 12:00 AM EDT) -- Lawmakers' doubts about the integrity of a Vytorin study they requested from manufacturers Merck & Co. and Schering-Plough Corp. and concerns that the drug causes cancer have not been abated after reviewing the full study.

The two congressmen leading the U.S. House Committee on Energy and Commerce's investigation, Reps. John Dingell and Bart Stupak, both Democrats from Michigan, issued a letter to the pharmaceutical companies Tuesday after viewing the report they requested last month as part of the probe into the cholesterol drug’s safety and effectiveness....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.